Adcetris sales and marketing update

The U.K.’s NICE issued draft guidance recommending against the use of Adcetris brentuximab vedotin from Takeda to treat CD30-positive Hodgkin’s lymphoma. Specifically, the

Read the full 235 word article

User Sign In